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To investigate the relationship between HPC2/ELAC2 and prostate cancer risk, we performed the following analyses:
(1) a linkage study of six markers in and around the HPC2/ELAC2 gene at 17p11 in 159 pedigrees with hereditary
prostate cancer (HPC); (2) a mutation-screening analysis of all coding exons of the gene in 93 probands with HPC;
(3) family-based and population-based association study of common HPC2/ELAC2 missense variants in 159 pro-
bands with HPC, 249 patients with sporadic prostate cancer, and 222 unaffected male control subjects. No evidence
for linkage was found in the total sample, nor in any subset of pedigrees based on characteristics that included age
at onset, number of affected members, male-to-male disease transmission, or race. Furthermore, only the two
previously reported missense changes (Ser217Leu and Ala541Thr) were identified by mutational analysis of all
HPC2/ELAC exons in 93 probands with HPC. In association analyses, family-based tests did not reveal excess
transmission of the Leu217 and/or Thr541 alleles to affected offspring, and population-based tests failed to reveal
any statistically significant difference in the allele frequencies of the two polymorphisms between patients with
prostate cancer and control subjects. The results of this study lead us to reject the three alternative hypotheses of
(1) a highly penetrant, major prostate cancer–susceptibility gene at 17p11, (2) the allelic variants Leu217 or Thr541
of HPC2/ELAC2 as high-penetrance mutations, and (3) the variants Leu217 or Thr541 as low-penetrance, risk-
modifying alleles. However, we did observe a trend of higher Leu217 homozygous carrier rates in patients than in
control subjects. Considering the impact of genetic heterogeneity, phenocopies, and incomplete penetrance on the
linkage and association studies of prostate cancer and on the power to detect linkage and association in our study
sample, our results cannot rule out the possibility of a highly penetrant prostate cancer gene at this locus that only
segregates in a small number of pedigrees. Nor can we rule out a prostate cancer–modifier gene that confers a
lower-than-reported risk. Additional larger studies are needed to more fully evaluate the role of this gene in prostate
cancer risk.
Introduction
Using a genomewide screen together with positional
cloning, Tavtigian et al. (2001) identified the HPC2/
ELAC2 gene (MIM 605367) on chromosome 17 as a
prostate cancer (MIM 176807) susceptibility gene in
large, high-risk Utah pedigrees. A genomewide screen in
eight Utah pedigrees provided suggestive evidence for
linkage at 17p11 near marker D17S520, and fine-map-
ping studies using dense markers in the region in a larger
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set of pedigrees (total of 33) provided significant evi-
dence for linkage, with a maximum two-point LOD
score of 4.5 at D17S1289. The evidence for linkage in
an additional 94 pedigrees was positive but much
weaker, with a peak LOD of 0.44 in this region. Se-
quence analysis of HPC2/ELAC2 identified four se-
quence variants, including a rare frameshift, and three
missense changes, two of which were common in the
study population. These latter two polymorphisms result
in a Ser-to-Leu change at amino acid 217, and an Ala-
to-Thr change at amino acid 541. These two polymor-
phisms were reported to segregate with prostate cancer
in two high-risk pedigrees. In addition, the two poly-
morphisms were found to be associated with the diag-
nosis of prostate cancer, by comparing the carrier rates
of Leu217 and/or Thr541 among patients with heredi-
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tary prostate cancer (HPC), unaffected members of ped-
igrees with HPC, and unaffected men who had married
into the pedigrees. Specifically, the overall allele fre-
quency of Leu217 was 30%, and the frequency of
Leu217 homozygotes was higher in patients with HPC
(57 [13.3%]/429) than in either unaffected members of
pedigrees with HPC (220 [9.3%]/2371; ) or inPp .013
unaffected men who had married into the pedigrees (9/
148 [6.1%], ). The overall allele frequency ofPp .026
Thr541 was 4% and its carrier rates were higher in
patients with HPC (42 [9.8%]/429) than in unaffected
men who had married into the pedigrees (5 [3.4%]/148;
). There is strong linkage disequilibrium (LD)Pp .022
between the two polymorphisms, even though they are
∼15 kb apart. All of the Thr541 variants are observed
on Leu217 chromosomes (Tavtigian et al. 2001).
The finding of the association between the two poly-
morphisms in HPC2/ELAC2 and prostate cancer risk
was examined in an independent study of 359 incident
prostate cancer case subjects unselected for family his-
tory and 266 male control subjects without prostate
cancer (Rebbeck et al. 2000). The frequencies of the
Leu217 allele was 30.8%, 31.5%, and 31.6%, in the
359 case subjects, 258 age- and race-matched control
subjects, and 383 total control subjects, respectively.
There was no significant difference of the Leu217 carrier
rates in the case subjects (52.1%) and in the control
subjects (53.1%). The frequencies of Thr541 allele were
3.8%, 1.8%, and 2.9% in the 359 case subjects, 258
age- and race-matched control subjects, and all 383 con-
trol subjects (matched and unmatched), respectively.
The Thr541 carrier rate was reported to be significantly
higher in the case subjects (7.5%) than in the matched
control subjects (3.5%), with an odds ratio (OR) of 2.37
(95% confidence interval [CI] 1.06–5.29), with the
Leu217/Thr541 variant being estimated to account for
∼5% of prostate cancer case subjects in the general pop-
ulation. Interestingly, the Thr541 carrier rate in case
subjects was not significantly higher than the frequency
observed for the complete control group (5.7%). Reb-
beck et al. also reported that the Thr541 allele was only
observed on the background of Leu217.
To examine the above findings of linkage and asso-
ciation between the HPC2/ELAC2 and prostate cancer
risk, we performed linkage and mutational analyses in
families with HPC and association studies in two data
sets. We genotyped four microsatellite markers sur-
rounding the HPC2/ELAC2 gene and the Leu217 and
Thr541 polymorphisms within the gene in 159 families
with hereditary prostate cancer. We have also genotyped
the two polymorphisms in 249 sporadic prostate cancer
case subjects, and 211 non–prostate cancer male control
subjects. In addition, we performed mutational analysis
on all HPC2/ELAC exons by heteroduplex analysis and
direct sequencing of 93 patient DNA samples.
With these data, we can test the following alternative
hypotheses. (1) If the HPC2/ELAC2 is a major, high-
penetrance gene for prostate cancer, we would expect
to observe significant linkage at 17p11 in the 159 total
families with HPC and/or mutations in the gene seg-
regating with disease phenotype. (2) If the variants
Leu217 or Thr541 of the gene HPC2/ELAC2were high-
penetrance mutations, we would expect to observe sig-
nificant linkage, in the subset of families that carry the
Leu217 and/or Thr514 alleles, and over-transmission of
the Leu217 and/or Thr541 alleles in these families. (3)
If the variants Leu217 or Thr541 are high-prevalence
but low-penetrance modifier alleles, we would expect
to observe higher frequency of the Leu217 and/or
Thr514 allele carrier in sporadic case subjects, com-
pared with unaffected control subjects.
Families and Methods
Ascertainment of Families
All 159 families with HPC were ascertained and stud-
ied at the Brady Urology Institute at Johns HopkinsHos-
pital. Families were ascertained from three sources.
Sixty-eight families were ascertained through referrals
generated in response to a letter by one of us (PCW) to
8,000 urologists throughout the United States. The sec-
ond source, from which 37 families were identified, was
family-history records of patients seen at Johns Hopkins
Hospital for treatment of prostate cancer. The remaining
families (54) came from the respondents to articles,
which appeared in various lay publications, describing
our studies of families with HPC. Prostate cancer di-
agnosis was verified by medical records for each affected
man studied. Age at diagnosis of prostate cancer was
confirmed either through medical records or through
two other independent sources. The mean age at diag-
nosis was 64.3 for the case subjects in these families;
84% of the families are white, and 8.8% are black.
All sporadic prostate cancer case subjects were re-
cruited from among patients who underwent treatment
for prostate cancer at the John Hopkins Hospital. The
diagnosis of prostate cancer for all these subjects was
confirmed by pathology reports. Preoperative prostate-
specific antigen (PSA) levels, Gleason score, and path-
ological stages were available for 92, 244, and 245 of
the 249 sporadic case subjects, respectively. Mean age
at diagnosis for these case subjects was 58.6. Family
histories were not available. More than 93% of the case
subjects are white, and 3.2% are black.
Two hundred and twenty-two control subjects were
selected from among men who participated in screening
programs for prostate cancer. After excluding those who
had abnormal results of a digital rectal examination
(DRE) or abnormal PSA levels (4 ng/ml), 211 were
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eligible for the study. The mean age at examination was
58 years. More than 86% of the eligible control subjects
are white and 7.1% are black. About 5.6% of the eligible
control subjects have a brother(s) or father affected with
prostate cancer. The affection status of relatives was ob-
tained by interview of the probands.
Marker Genotyping
Four microsatellite markers surrounding the HPC2/
ELAC2 gene were genotyped in 159HPC families. These
markers were selected from Marshfield Comprehensive
Human Genetic Maps (Broman et al. 1998) and cover
∼18 cM from 17p13 to 17q1. Multiplex PCR using flu-
orescently labeled primers (either fam, hex, or ned) was
performed, and the resulting PCR fragments were sep-
arated by means of capillary electrophoresis using an
ABI 3700 DNA Analyzer (Applied Biosystems). The
genotypes were scored using ABI Genotyper software.
A modified version of the program Linkage Designerwas
used to bin the alleles and check inheritance. The output
from Linkage Designer was then analyzed further for
any inconsistencies by use of the program LINKAGE
(Lathrop et al. 1984; Cottingham et al. 1993) without
disease-phenotype information. Marker allele frequen-
cies were estimated from the independent individuals in
the data set (i.e., genetically unrelated individuals based
on all the available information).
Two single-nucleotide polymorphisms (SNPs) in the
HPC2/ELAC2 gene were genotyped for all subjects using
PCR and restriction enzyme digestion, as described by
Rebbeck et al. (2000), with the following modifications:
for the region containing the Ser217Leu variant, PCR
was performed in a 10-ml volume consisting of 30 ng
genomic DNA, 0.2 mM each primer, 0.2 mM each dNTP,
1.5 mM MgCl2, 20 mM Tris-HCl, 50 mM KCl and 0.5
U Taq polymerase (Life Technologies). The primers were
m5A (5′-CATTCCCATGTATGAACGTCT-3′) and m5Q
(5′-AGGAAACAGCTATGACCATCTACAAGCATTA-
CAAGGCAGAG-3′). These primers amplified a 276-bp
fragment. PCR cycling conditions were as follows: 95C
for 3 min, followed by 28 cycles of 95C for 30 s, 55C
for 30 s, and 72C for 20 s, with a final extension of
72C for 2 min; 5 ml of PCR products were digested with
TaqaI (New England Biolabs) at 65C for 2 hours. Geno-
types were read on 2% agarose gels. Among Ser/Ser
individuals, 172- and 104-bp products were observed,
whereas Leu/Leu produced an uncut 276-bp band. For
the region containing the Ala541Thr variant, PCR was
performed as with the Ser217Leu variant. The primers
were m15A (5′-CCAGCCTTTGTGTAAGTCTAC-3′)
and m15P (5′-TCTGGGCAAGTTTGGAAGC-3′). A
495-bp fragment was amplified. PCR cycling conditions
were the same as for Ser217Leu, except that the an-
nealing temperature was 57C; 5 ml of PCR products
were then digested with Fnu4HI (New England Bio-
labs) at 37C for 2 h, and the fragments were separated
on 2% agarose gels. Among Thr/Thr individuals, 162-
bp products were observed; for Ala/Ala, 110-bp prod-
ucts were observed. Genotyping of the two SNPs in 159
HPC probands was performed in three independent lab-
oratories (Wake Forest, National Human Genome Re-
search Institute, and Johns Hopkins University) as a
quality-control measure. All the genotyping results were
identical.
Genomic Mutational Analysis
For HPC2/ELAC2 exons, PCR was performed in 50-
ml reactions consisting of 20 ng genomic DNA, 10 mM
dNTPs, 10# PCR Buffer (Gibco BRL), 4.5 mMMgCl2,
0.5 U Platinum Taq DNA polymerase (Gibco BRL),
0.5 U AmpliTaq Gold (Applied Biosystems), and 10
pmol of each forward and reverse primer (Gibco BRL).
PCR cycles consisted of 95C for 14 min, followed by
35 cycles of 95C for 30 s, 55C for 30 s, 72C for 45
s, and a final extension at 72C for 5 min. PCR products
were denatured for 3 min at 95C and then were rean-
nealed gradually over 30 min using a 95C to 65C tem-
perature gradient. The optimal melting temperature for
each PCR amplicon was obtained by analysis of wild-
type sequence, using an algorithm at the Stanford De-
naturing High-Performance Liquid Chromatography
(DHPLC) Web site.
DHPLC
DHPLC heteroduplex analysis was performed using
automated HPLC instrumentation equipped with an an-
alytical 2.1# 75–mm Eclipse dsDNA column (Agilent
Technologies). The analytical gradient was composed of
Buffer A (100 mM triethylammonium acetate and 0.10
mM EDTA) and Buffer B (100 mM triethylammonium
acetate, 0.10 mM EDTA, and 25% acetonitrile) with a
flow rate of 0.4 ml/min. The injection volume of each
PCR sample was 4 ml. The analysis time for each sample
was 10 min, including a column wash and an equili-
bration step.
Sequencing Analysis
PCR products were purified using the Qiagen PCR
purification kit (Qiagen) with the Qiagen BIOROBOT
9600 dual vacuum system. One-half–volume sequencing
reactions were prepared in a 96-well format using the
3700 Big Dye Terminator Chemistry (Applied Biosys-
tems) as follows: 6 ml of purified PCR product, 4 ml Big
Dye Terminator reagent, and 1 ml of 5 pmol/ml of primer.
Exons 7, 11, and 17 were sequenced usingM13 forward
and reverse primers. All remaining exonswere sequenced
using corresponding primers (table 1). Sequencing re-
actions were performed using the following conditions:
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Table 1
Primers Used for Mutation Analysis
EXON
PRIMER SEQUENCE
SIZE
(bp)Forward Reverse
1 CCGCTTGAGACGCTCTAGTAT CTGTCAGCACTTTCGGAGC 735
2 AATGGTGTCAGAGAGTTTACAG ATAGCAAAAGTGGTCCTTGTTC 214
3 TTTATAGCAAAAGTGGTCCTTG GAGGCTGGTGGGAAGTCTC 178
4 CCTTGCTGCTTCACCCTAG CGTAGCAGCACATATAAAGCA 578
5 CTACATTTGTTCAACCATAACTG CATCAACATCAAACCTCAAAATC 208
6 TCGTGTCAGATTCCCACCATA ACGGATGTCTGACTTATGCCT 388
7 CATTCCCATGTATGAACGTCT TCCTTCTTCCTGGGCTTACTAT 335
8 AGTGTCTTCAGCCTTTGTATTG TGAGACAAGAAGAGATAGCAGAT 325
9 TAAAACCAACCTTCTTCATTAG CATCGCTCCCATCATTGCT 245
10 GGCTTCTGGGGACTCACTG CTACAGACACCACTTTTGAAGG 251
11 GTATCCACAAAGAGACCAGAAG TAAGTCACTGTTGGTAGTTGGTG 448
12 GCTTGCCAGATACAGGAATC CACCTGCCTAAACTTTCTGT 433
13 GAACACCTCATCCTCATTACCA CCATGAATGTGTTTTGTCTCTT 316
14 GTTTCCGCTGTAAGGTAGTGT CCACATAGTAAATGTTCCAG 266
15 TGCTAGTGGGTAGAGGTCAG CATTCTAACCTGGCTTTCAGT 528
16 TGTGAAGACGGGATAACCTGA TGCGGTATCAAGCCCTGTC 534
17 CCAGCCTTTGTGTAAGTCTAC CTTCCAAACTTGCCCAGA 392
18 CGCTTTCTGCCTGTGACAT GCATTGGCTGAAGGACAGAA 634
19 CACTTGATGGGCGTTCTGAG GCATTGGCTGAAGGACAGAA 394
20 GGGTTCTCCAGCCAAAGACT CAGAGCCTTCCAGCCCCACA 256
21 AAGAGGTAAGGGGCACAGC GCAGAGGCAGGAGACTCAGA 313
22 GCTGAGTGTTGAGACCAGGA GAGCAGCCGTCGTTTGTCT 252
23 GGGAGATGGTGCTGGCTAC ATCTACCCATCACTAACCAGG 439
24 TTGATTTTGAGAGCATCTGGAC CAGTGGGTCTAAGTGTCCGAG 860
95C for 3 min, 98C for 45 s, 50C for 10 s, 60C for
4 min, followed by 25 cycles of 98C for 15 s, 50C for
10 s, 60C for 4 min.
Sequencing reactions were subsequently purified using
a 96-well Sephadex plate (preparation of Sephadex G-
50 containing microtiter filter plates from the University
of Oklahoma Advanced Center for GenomeTechnology)
and were dried in a Speedvac (Savant). Samples were
rehydrated and denatured in 10 ml Hi-Di formamide
loading buffer at 95C for 3 min. Samples were electro-
phoresed on a 3700 DNA Analyzer (Applied Biosys-
tems), according to the manufacturer’s protocols.
Statistical Analyses
Hardy-Weinberg equilibrium (HWE) tests for all
markers and LD tests between all pairs of markers were
performed using independent individuals of HPC fam-
ilies and all sporadic case subjects and non-prostate can-
cer control subjects (GDA software, Weir et al. 1996).
The HWE tests were based on exact tests, in which a
large number of the possible arrays are generated by
permuting the alleles among genotypes, and the pro-
portion of these permuted genotypic arrays that have a
smaller conditional probability than the original data is
calculated. The LD tests were based on an exact test,
assuming multinominal probability of the multilocus
genotype, conditional on the single-locus genotype (Zay-
kin et al. 1995). A Monte Carlo simulation was used to
assess the significance, by permuting the single-locus
genotypes among individuals in the sample to simulate
the null distribution. The empirical P values of both
HWE and LD tests were based on 10,000 replicate sam-
ples. All six markers are in HWE in 159 probands with
HPC. Both SNPs are in HWE in both case and control
subjects.
Multipoint linkage analyses were performed using
both parametric and nonparametric methods, imple-
mented by GENEHUNTER-PLUS (Kruglyak et al. 1996;
Kong and Cox 1997). Two genetic models were used
for the parametric analyses. The autosomal dominant
model was the same as that used by Smith et al. (1996).
Under this model, the disease gene frequency of .003,
incomplete penetrance, and phenocopies were assumed.
Specifically, affected men were assumed to be disease-
gene carriers with a fixed 15% phenocopy rate, and all
unaffected men 75 years old and all women were as-
sumed to be of unknown phenotype. In men 175 years
old, the lifetime penetrance of gene carriers was esti-
mated to be 63%, and the lifetime risk of prostate cancer
for noncarriers was 16% in this age class. A similar
autosomal recessive model was also used, except that
the disease-gene frequency was set at .077, giving the
same population disease frequency (Berry et al. 2000b).
Linkage in the presence of heterogeneity was assessed
by use of Smith’s admixture test for heterogeneity (Ott
1998). In this test, two types of families are assumed:
one type linked to the disease locus with a proportion
Xu et al.: Linkage and Association of HPC2/ELAC2 905
Table 2
Multipoint Linkage Results in 159 Families with HPC
MARKER
DISTANCE
(cM)a
HLODb HLODb (RECESSIVE MODEL) ALLELE-SHARING LOD
Two Point Multipoint Two Point Multipoint Two Point Multipoint
D17S786 10.9 0 0 0 0 0 0
Ser217Leu 15.5 0 0 0 0 0 0
Ala541Thr 15.5 .14 0 .13 0 .03 0
D17S799 15.9 0 0 0 0 .07 0
D17S1843 22.1 0 0 0 0 .05 0
D17S783 28 0 0 0 0 .01 0
a Distance from 17 pter.
b HLOD p LOD score, assuming locus heterogeneity.
of a and the other type not linked, with the proportion
1  a. A maximum-likelihood approach was used to
estimate the proportion of linked families (a), by max-
imization of the admixed LOD score.
For the nonparametric analysis, the estimated marker
identical by descent (IBD) sharing of alleles for the var-
ious affected relative pairs was compared with its ex-
pected values under the null hypothesis of no linkage.
A statistic Zall in the program was used (Whittemore and
Halpern 1994). Allele-sharing LOD scores were then cal-
culated, using the computer program ASM (Kong and
Cox 1997), on the basis of the statistic Zall with equal
weight assigned to all families.
Family-based association tests were performed for all
six markers in the 159 families with HPC, using the
software package FBAT (Laird et al. 2000). Unlike the
classic transmission/disequilibrium test (TDT), which is
limited to a specific pedigree structure (one genotyped
proband and two genotyped parents per pedigree), the
FBAT uses data from nuclear families, sibships, or a
combination of the two to test for linkage and LD be-
tween traits and genotypes. The test for linkage is valid
when multiple affected members in each pedigree are
used, and the power to detect linkage is increased if there
is an association. The test for association is valid if the
empirical variance is used to account for correlation be-
tween transmissions in families when linkage is present.
In brief, the FBAT determines an S statistic from the
data, which is the linear combination of offspring geno-
types and phenotypes. The distribution of the S statistic
is generated by treating the offspring genotype data as
random and conditioning on the phenotypes and paren-
tal genotypes. When the marker is biallelic, a Z statistic
(together with its corresponding P value) is calculated.
When the marker is multiallelic, a x2 test is performed,
with the number of df being equal to the number of
alleles.
Population-based association tests were performed
for the two polymorphisms in patients with prostate
cancer and in control subjects without prostate cancer.
An unconditional logistic regression is used to test for
association between genotypes and affection status,
adjusting for potential confounding variables such as
age. The association tests were also performed only
for white subjects to decrease the potential confound-
ing effects of population stratification.
Results
Hardy-Weinberg Equilibrium and LD Tests
All four microsatellite markers and two SNPs are
in HWE in this study population. The empirical P val-
ues for the HWE tests were .51, .48, .08, .52, .40, and
.60 for D17S786, Ser217Leu, Ala541Thr, D17S799,
D17S1843, and D17S783, respectively. There was a
strong LD between the two SNPs ( ), and almost6P ! 10
all Thr541 allele carriers also carried Leu217. We ob-
served three white patients with sporadic prostate cancer
who had the haplotype Thr541 and Ser217.
Parametric and Nonparametric Linkage Analyses
There was no evidence for linkage between prostate
cancer–susceptibility genes andmarkers at 17p13-17q11
in the 159 pedigrees with HPC (table 2). The total in-
heritance information in the 159 pedigrees using these
six markers is intermediate (0.58–0.67). Parametric and
nonparametric linkage analyses provided similar results.
The multipoint LOD scores, under the assumption of
heterogeneity and under either the dominant or the re-
cessive model, were 0 across the region. Sixteen pedi-
grees had LOD scores (under the dominantmodel)0.3,
and three pedigrees had LOD scores 0.6. The highest
LOD score, 0.97, occurred in a pedigree with six affected
members (two affected siblings, an affected father, and
three affected paternal uncles [father and one uncle with-
out genotype]). The nonparametric allele-sharing LOD
scores were 0 across the region.
The stratified linkage analyses did not provide evi-
dence for linkage in any subsets of pedigrees (table 3).
The allele-sharing LOD scores were 0 across the region
regardless of age at diagnosis. In addition, allele-sharing
LOD scores were 0 in pedigrees with three, four, and
more than four affected members; in white and black
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Table 3
Allele-Sharing LOD Scores in Subsets of Families with HPC
FAMILY CHARACTERISTIC
NO. OF
PEDIGREES
LOD SCORES WITH
D17S786 Ser217Leu Ala541Thr D17S799 D17S1843 D17S783
Proband age at diagnosis:
!65 79 .11 .02 .02 .03 .16 .19
65 80 0 0 0 0 0 0
No. of affected members:
3 29 0 0 0 0 0 0
4 40 0 0 0 0 0 0
5 90 .03 .18 .14 .19 .21 .1
Race:
White 133 0 0 0 0 .02 0
Black 14 0 0 0 0 0 0
Other 12 0 0 0 0 0 0
Male-to-male disease transmission:
Yes 98 0 .01 0 .01 .02 .1
No 60 0 0 0 0 0 0
Probands with Leu217 89 0 0 0 0 0 0
Probands with Thr541 17 0 0 0 0 0 0
subjects; and in pedigrees with and without male-to-
male disease transmission. When the linkage analyses
were limited to the 89 pedigrees in which probands are
Leu217 carriers or to the 17 pedigrees in which probands
are Thr541 carriers, no evidence for linkage was found.
Mutational Screens for All Exons
To directly assess the HPC2/ELAC2 gene for muta-
tions that may be segregating in the families with HPC
reported here, the complete coding region of the gene
was screened for sequence variants in 93 probands with
HPC. Although the two previously reported missense
changes were readily observed, no other DNA sequence
variants were found that altered the amino acid sequence
of HPC2/ELAC2.
Family and Population-Based Association Tests
Family-based linkage and association tests using a
multiallelic method did not provide evidence for either
linkage or LD between the markers and prostate can-
cer–susceptibility genes (table 4). The association tests
using the biallelic method were also performed for the
two single-nucleotide polymorphisms (SNPs). For the
SNP Ser217Leu, 84 nuclear pedigrees were informative
for the analysis. The observed S score was 187.0, and
the expected S score was 194.3 (empirical variance 40.3;
; ). For the SNP Ala541Thr, 24 nu-Zp 1.15 Pp .25
clear pedigrees were informative for the analysis. The
observed S score was 33.0, and the expected S score was
30.8 (variance 6.40; ; ). The resultsZp 0.87 Pp .38
were similar when the analyses were limited to white
subjects.
Allele frequencies of the two SNPs were compared
between patients with prostate cancer and control sub-
jects. To decrease the confounding effect of racial dif-
ferences, the comparison was limited to white subjects.
The allele frequencies for Leu217 were 34.0%, 29.2%,
and 27.2%, in the 134 probands with HPC, 228 patients
with sporadic disease, and 182 unaffected control sub-
jects, respectively. There was no statistically significant
difference in the frequencies between the HPC case sub-
jects and control subjects (Fisher’s exact test [FET]
), between the sporadic case subjects and controlPp .08
subjects (FET ), and between all case subjectsPp .58
and control subjects (FET ). The allele frequen-Pp .21
cies for Thr541 were 6.1%, 4.8%, and 4.4% in the
probands with HPC, the patients with sporadic disease,
and the unaffected control subjects, respectively. No sig-
nificant difference was observed in the allele frequencies
between the probands and control subjects (FET Pp
), between the patients with sporadic disease and the.45
control subjects (FET ), or between all patientsPp .87
and control subjects (FET ).Pp .65
Genotype frequencies of the two SNPs were also com-
pared in an analysis restricted to white subjects (table
5). There was a trend toward higher Leu217 homozy-
gous rates in the patients with HPC (11.2%) and in the
patients with sporadic disease (8.3%) than in the control
subjects (7.7%); however, the difference was not statis-
tically significant. There was no statistical difference in
the Thr541 carrier rates in the patients with HPC
(10.5%), in the patients with sporadic disease (9.0%),
or in the unaffected control subjects (9.0%). When the
two SNPs are considered together, no significant differ-
ence in the frequencies was found. The frequencies of
individuals carrying both Leu217 and Thr541 were
10.4% in the HPC case subjects, 8% in the sporadic
case subjects, and 8.8% in the unaffected control
subjects.
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Table 4
Results of Family-Based Association Test in
159 Families with HPC
Marker
No. of
Carriers dfa x2 P
D17S786 11 6 2.4 .88
Ser217Leu 2 1 1.42 .23
Ala541Thr 2 1 .61 .44
D17S799 10 6 2.89 .82
D17S1843 14 6 4.91 .55
D17S783 10 7 6.11 .53
NOTE.—Families comprised 653 and 97
affected and unaffected subjects, respectively.
a Alleles observed in !10 subjects were not
included in the analysis.
Table 5
Genotypes of Ser217Leu and Ala541Thr in Patients with HPC, Patients with Sporadic Disease, and Unaffected Control Subjects
(White Only)
Ser217Leu Ala541Thr
NO. OF
CONTROL
SUBJECTS
NO. OF
PATIENTS
WITH ORa (95% CI) OF
SPCb HPC
SPC vs. Control
Subjects
HPC vs. Control
Subjects
All Patients
vs. Control Subjects
Ser/Ser 97 114 58 1 1 1
Ser/Leu 71 95 61 1.14 (.75–1.71) 1.45 (.90–2.35) 1.39 (.98–1.97)
Leu/Leu 14 19 15 1.14 (.54–2.40) 1.63 (.71–3.73) 1.34 (.68–2.63)
Any Leu 85 114 76 1.14 (.77–1.68) 1.49 (.94–2.35) 1.26 (.87–1.84)
Ala/Ala 166 211 111 1 1 1
Ala/Thr 16 20 11 .98 (.49–1.96) .95 (.42–2.15) .99 (.52–1.87)
Thr/Thr 0 1 2
Any Thr 16 20 13 1.03 (.52–2.04) 1.16 (.53–2.55) 1.09 (.58–2.05)
Ser/Ser Ala/Ala 97 110 55 1 1 1
Any Leu Ala/Ala 69 97 56 1.25 (.82–1.89) 1.43 (.87–2.35) 1.33 (.90–1.95)
Ser/Ser Any Thr 0 3 0
Any Leu Any Thr 16 17 13 .94 (.45–1.95) 1.37 (.61–3.11) 1.10 (.57–2.14)
a All ORs were adjusted for age.
b SPC p sporadic prostate cancer.
We also examined the relationships of Leu217 and
Thr541 frequencies and Gleason scores and pathological
stages in sporadic prostate cancer case subjects. There
was no statistically significant difference in the genotypic
frequencies of the two SNPs between the groups with
low (6) and high (7) Gleason scores or between the
groups with disease confined to the prostate and the
group with non–organ-confined disease (table 6).
Discussion
We tested several alternative hypotheses in the current
study. The first hypothesis—that HPC2/ELAC2 is a high-
prevalence, high-penetrance major gene for prostate can-
cer—was rejected, because linkage results using both
parametric and nonparametric methods in the 159 ped-
igrees with HPC did not provide any evidence for link-
age. The finding of no novel mutations in the coding
region of HPC2/ELAC2 in 93 probands with HPC is
consistent with this conclusion. The lack of evidence for
linkage from the parametric analyses (under either a
dominant or recessive model) is unlikely to have resulted
solely from the misspecification of the parameters in the
genetic model. The impact of misspecification of pene-
trance estimates on the linkage results is small, as long
as a dominant or recessive model is correctly specified
(Clerget-Darpoux et al. 1986).
The second hypothesis—that the HPC2/ELAC2 was
a less prevalent, high-penetrance major gene—was also
rejected, because linkage evidence was not found when
heterogeneity was assumed, which tested for a subset
of pedigrees linked to this gene or region. No evidence
for linkage was found in predefined subsets of families
based on the pedigree characteristics, such as age at
diagnosis, number of affected members per pedigree,
male-to-male disease transmission, and race. Finally, no
evidence for linkage was observed in subsets of pedi-
grees in which probands carried the Leu217 and/or
Thr541 alleles.
The third alternative hypothesis—that the HPC2/
ELAC2 is a common, low-penetrance modifier gene—
was rejected, because neither family-based nor popu-
lation-based tests found evidence for association be-
tween the genotypes at Ser217Leu and/or Ala541Thr
and prostate cancer risk. Leu217 and/or Thr541 carrier
rates in probands with HPC or in the patients with
sporadic disease were not significantly increased, com-
pared with unaffected control subjects.
Although these alternative hypotheses were rejected
because of the absence of statistically significant differ-
ences, the results should be interpreted cautiously, be-
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Table 6
Genotypes of Ser217Leu and Ala541Thr in White Men with
Sporadic Prostate Cancer
ALLELE
NO. (%) OF PATIENTS WITH
Gleason Score Pathological Stagea
6 7 OC NOC
Ser217Leu:
Ser/Ser 42 72 32 (45.07) 82 (52.23)
Ser/Leu 38 57 33 (46.48) 62 (39.49)
Leu/Leu 6 (6.98) 13 (9.15) 6 (8.45) 13 (8.28)
Ala541Thr:
Ala/Ala 83 128 62 (87.30) 149 (92.55)
Ala/Thr 6 (6.74) 14 (9.79) 9 (12.68) 11 (6.83)
Thr/Thr 0 (0) 1 (.7) 0 (0) 1 (.62)
a OC p organ-confined disease; NOC p non–organ-confined
disease.
cause various forms of genetic heterogeneity, high phe-
nocopy rates, and incomplete penetrance in prostate
cancer can significantly decrease the power to detect
linkage and association of a true susceptibility gene.
Different modes of inheritance have been reported for
the transmission of prostate cancer in families, including
autosomal dominant and X-linkage modes (Woolf
1960; Carter et al. 1992; Hayes et al. 1995; Monroe et
al. 1995; Narod et al. 1995; Gro¨nberg et al. 1997;
Schaid et al. 1998; Cerhan et al. 1999; Schuurman et
al. 1999), and various loci have been reported as pros-
tate cancer–susceptibility genes, including HPC1 (MIM
601518; Smith et al. 1996; Cooney et al. 1997; Hsieh
et al. 1997; McIndoe et al. 1997; Eeles et al. 1998;
Neuhausen et al. 1999; Xu 2000), PCAP (MIM602759;
Berthon et al. 1998; Gibbs et al. 1999a; Whittemore et
al. 1999; Berry et al. 2000a), HPCX (MIM 300147; Xu
et al. 1998; Lange et al. 1999; Peters et al. 2001), CAPB
(MIM 603688; Gibbs et al. 1999b; Berry et al. 2000b),
and HPC20 (Berry et al. 2000b). With these various
forms of genetic heterogeneity, it would not be surpris-
ing that only a small proportion of pedigrees and pa-
tients had prostate cancer that was attributable to the
HPC2/ECLA2 gene. Furthermore, the high phenocopy
rate caused by high prevalence of the disease can prevent
the detection of linkage even in the pedigrees where the
HPC2/ECLA2 gene segregates (e.g., some affected in-
dividuals in these pedigrees with HPC could be non-
genetic case subjects) which lead to false recombinants
in the linkage analysis and to misclassification in the
association study. These problems could be com-
pounded by incomplete and age-dependent penetrance
of HPC2/ECLA2. Finally, some of the unaffected men
could be HPC2/ECLA2 gene carriers but remain un-
affected because of lack of background genes (modifier
genes) and/or lack of environmental risk factors.
To investigate the power to detect linkage in the 159
pedigrees with HPC in the presence of genetic hetero-
geneity, high phenocopy rate, and incomplete pene-
trance, we performed a computer simulation study using
FASTLINK. The dominant model, as described in the
Families and Methods section, which incorporates a
15% phenocopy rate and 63% penetrance by age 75
years, was used to simulate a disease gene that segre-
gates in the 159 pedigrees with HPC. A marker with
six equally frequent alleles was simulated to be linked
to the disease gene at a recombination fraction (v) of
.025, using these exact pedigree structures, affection
status, and availability of DNA. When 20% of the 159
pedigrees were linked to the disease gene, 46%, 17%,
and 6% of the 1,000 replicates reached allele-sharing
LOD scores of 1, 2, and 3, respectively. When one-third
of the 159 pedigrees were linked to the disease gene,
89%, 65%, and 40% times among the 1,000 replicates
reached allele-sharing LOD scores of 1, 2, or 3, re-
spectively. The simulation results suggested that we had
reasonable power to reach suggestive evidence for link-
age in our study sample only if one-third of the pedigrees
segregate the gene. When the proportion of pedigrees
that segregate the gene is below that level, the power is
very limited. Clearly, a much larger collection of pedi-
grees with HPC is needed to detect linkage of genes that
segregate in a small proportion of pedigrees.
Similarly, we estimated the power to detect an as-
sociation in our study sample. When the point estimates
of ORs and frequencies from Tavtigian et al. (2001) are
used, the power to detect an OR of 2.4 at the signifi-
cance level of .05, with a frequency of Leu217 homo-
zygous carrier rate of 6.1% in control subjects, is 87%
in our combined 364 patients and 182 control subjects.
The power to detect an OR of 2.9 at the significance
level of .05, with a frequency of any Thr541 carrier rate
of 3.4% in control subjects, is 69% in our combined
patient and control sample. However, if we consider the
lower estimates of the 95% CI of the reported ORs,
our study sample has very low power to detect this level
of effect. For example, if the Leu217 and Thr541 have
an OR of 1.3 each, our sample has only 18% and 13%
power, respectively.
Considering the difficulties in the linkage and asso-
ciation studies of complex diseases and the lack of
power to detect linkage and association of genes with
relatively small effects, our negative linkage and asso-
ciation results are not surprising. On the basis of our
linkage results, we probably can rule out anymajor gene
that segregates in a large number of pedigrees, but we
cannot rule out the possibility that a small proportion
of our pedigrees segregate a major gene in the region.
However, two pieces of evidence suggested that, even if
there is a major gene in the region that segregates in a
small number of pedigrees, it is unlikely that they are
the Leu217 and/or Thr541 variants of the HPC2/
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ECLA2 gene. The first piece of evidence comes from the
negative linkage results in pedigrees whose probands
carried the Leu217 and/or Thr541 alleles. If the variants
of the Leu217 and/or Thr541 were high-penetrancemu-
tations, we would expect to observe linkage in these
pedigrees. Although substantial phenocopies in these
pedigrees could disguise the linkage even if the variants
were high-penetrance mutations, it is difficult to use this
argument to explain the second piece of evidence that
the Leu217 and/or Thr541 alleles are not overtrans-
mitted to affected individuals in family-based associa-
tion tests.
Because our case-control sample has a reasonable
power to detect association when Leu217 homozygotes
have an OR of 2.4 or when Thr541 carriers have an
OR of 2.9, our negative association results suggested
that the Leu217 and Thr541, separately or together, are
not the modifier mutations that increase the prostate
cancer risk at the previously reported magnitude in our
study population. However, our results cannot rule out
the association between these variants and prostate can-
cer, if these variants confer lower risks than the point
estimates (in the lower ranges of the reported 95% CI).
In fact, although the differences were not statistically
significant, we observed higher homozygous Leu217
carrier rates in the patients (9.4%) than in the control
subjects (7.7%) (OR p 1.3). It is interesting that these
rates were highest in the patients with HPC (11.2%)
(ORp 1.6), intermediate in the patients with sporadic
disease (8.3%) (OR p 1.1), and lowest in the control
subjects (7.7%).
Our study is the first reported replication study to
investigate the linkage results at 17p11. The initial re-
port by Tavtigian et al. (2001) found a maximum two-
point LOD of 4.5 and a maximum three-point LOD of
4.3 in the 17p11 region in the first 33 pedigrees. They
found a much weaker linkage in the additional 94 ped-
igrees. Several factors may explain the difference be-
tween their study and ours. Most of their pedigrees are
large. The mean numbers of affected and genotyped
affected members were 18.9 and 5.5 per pedigree, re-
spectively. Themean numbers of affected and genotyped
affected members were only 5.1 and 3.3, respectively,
in our study. Interestingly, the most notable positive
LOD scores in our study came from the 90 pedigrees
with five or more affected members. The Utah pedigrees
may be more homogeneous in both genetic and envi-
ronmental background than our study pedigrees. The
study by Tavtigian et al. mainly used two-point or three-
point methods because of the large size of the pedigrees.
These linkage methods are sensitive to allele frequencies,
and false-positive linkage can arise when marker allele
frequencies are wrongly assumed (Ott 1998). This is
especially critical in the study of prostate cancer, because
most parental genotype data are missing. Our linkage
analyses were based on both two-point and multipoint
analyses and thus were robust to the incorrect estimates
of marker allele frequencies.
Our study is the second reported replication study to
investigate the association between the two common
HPC2/ELAC2 sequence variants and prostate cancer
risk. For the Ser217Leu missense change, Tavtigian et
al. (2001) found significantly higher homozygous
Leu217 carriers in the related patients (13.3%) than in
the unaffected related pedigree members (9.3%) or in
the unrelated married-in unaffected males (6.1%). Reb-
beck et al. (2000) did not report the homozygous
Leu217 carrier rate in their study but found lower
Leu217 carrier rates in the patients (30.8%) than in the
control subjects (31.5%). We report here a higher
Leu217 homozygous carrier rate in probands with HPC
(11.2%) and in the patients with sporadic disease
(8.3%) than in the control subjects (7.7%), although
this difference is not statistically significant. For the
Ala541Thr variant, Tavtigian et al. (2001) found a sig-
nificantly higher Thr541 carrier rate in the related pa-
tients (9.8%) than in the unrelated married-in unaf-
fected men (3.4%). Rebbeck et al. (2000) reported a
marginally significant, higher Thr541 carrier rate in the
patients (7.5%) than in the 266 age- and race-matched
control subjects (3.5%). However, the Thr541 carrier
rate was 5.7% in their 383 control subjects. We found
no difference in the Thr541 carrier rates in the patients
with HPC (10.5%), in patients with sporadic disease
(9.0%), or in unaffected control subjects (9.0%). As an
additional control population, we genotyped 90 inde-
pendent subjects (all whites) from one of our nonpros-
tate cancer study populations (ages 45–65 years). Al-
though the prostate cancer status was unknown for this
population, it represents general population control
subjects. In this population, we found a similar fre-
quency for Thr541 carrier rate (11.1%) (J.X. and L.Z.,
unpublished data).
Although the differences between studies are unex-
plained, several of the following factors may contribute:
First, the point estimates of the ORs in the study by
Tavitigian et al. (2001) could be overestimated, because
the case subjects were not independent; most of their
study pedigrees are large, and if some of the pedigrees
were linked to this chromosomal region and the affected
individuals carried the variants, they could inflate the
frequency of the variants in the case subjects. Second,
the young age of some of the control men may lead to
potential misclassification, thereby decreasing the
power to detect association. Even though the age dif-
ferences between case and control subjects were not
statistically significant and the ORs were adjusted for
age, some of the younger control subjects in the study
reported here (40–50 years of age) may develop prostate
cancer later. Third, population stratification may lead
910 Am. J. Hum. Genet. 68:901–911, 2001
to false-positive findings. Although this is unlikely, be-
cause race was matched in the two positive association
studies, it is still possible that there are different genetic
backgrounds between case and control subjects within
the whites. The present study employed a family-based
association test, which is robust to population stratifi-
cation. Fourth, genotyping error is a potential problem
in case-control studies. Although caution has been ex-
ercised and some genotypes were confirmed by multiple
methods (Rebbeck et al. 2000), genotyping error in
other subjects cannot be ruled out. It is worth noting
that all the significant findings were marginal and that
one misclassified genotype may change the results. To
address this issue in our study, genotypes of the 159
HPC probands were confirmed by three independent
laboratories.
Caution is warranted when interpreting and gener-
alizing from the results of the present population-based
association study. The case subjects collected in our
study had early mean age of onset and thus may rep-
resent more hereditary case subjects. The potential bias
could be two ways, either bias toward a significant find-
ing if the HPC2/ELAC2 contributing to the suscepti-
bility or bias against a significant finding if other com-
peting major locus contributing to the susceptibility in
these subjects. The control subjects in our study came
from a prostate cancer screen population; the group
therefore is likely to be at high risk (because of self
selection). Although this could partially account for the
higher frequency (compared with the studies of Tavti-
gian et al. [2001] and Rebbeck et al. [2000]) of the
suspected alleles observed in our control subjects, we
think the impact is limited for the following three rea-
sons. First, all the control subjects were carefully ex-
amined and had normal DRE and PSA results. Thus,
they are unlikely to be case subjects, at least at the time
of examination. Second, very few of the control subjects
have a positive family history. We collected extensive
information on family history of the control subjects,
and only six control subjects reported positive family
history (defined as affected father and/or brothers)
among 182 white control subjects. Furthermore, when
we performed additional analysis with the six individ-
uals excluded, the results were similar. Third, the fre-
quency of the suspect alleles in 90 additional control
subjects was similar to the screen control subjects.
In summary, the results of the study reported here are
not consistent with a major role for HPC2/ELAC2 as
a prostate cancer susceptibility gene. In addition, we
find no significant evidence that the Leu217 or Thr541
variants of the HPC2/ELAC2 increase prostate cancer
risk in our study population.
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